WO2004029631A3 - Verfahren zur identifizierung bhs-spezifischer proteine und fragmente davon - Google Patents

Verfahren zur identifizierung bhs-spezifischer proteine und fragmente davon Download PDF

Info

Publication number
WO2004029631A3
WO2004029631A3 PCT/EP2003/009968 EP0309968W WO2004029631A3 WO 2004029631 A3 WO2004029631 A3 WO 2004029631A3 EP 0309968 W EP0309968 W EP 0309968W WO 2004029631 A3 WO2004029631 A3 WO 2004029631A3
Authority
WO
WIPO (PCT)
Prior art keywords
endothelial cells
bhs
fragments
capillary endothelial
cerebral
Prior art date
Application number
PCT/EP2003/009968
Other languages
English (en)
French (fr)
Other versions
WO2004029631A2 (de
Inventor
Sabine Wolf
Martina Jaeger
Thorsten Bangsow
Carmen Bangsow
Dominik Jordan
Bernhard Pelzer
Thomas Oppolzer
Original Assignee
Frankgen Biotechnologie Ag
Sabine Wolf
Martina Jaeger
Thorsten Bangsow
Carmen Bangsow
Dominik Jordan
Bernhard Pelzer
Thomas Oppolzer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10/527,788 priority Critical patent/US20060172300A1/en
Application filed by Frankgen Biotechnologie Ag, Sabine Wolf, Martina Jaeger, Thorsten Bangsow, Carmen Bangsow, Dominik Jordan, Bernhard Pelzer, Thomas Oppolzer filed Critical Frankgen Biotechnologie Ag
Priority to EP03757804A priority patent/EP1588172A2/de
Priority to AU2003273841A priority patent/AU2003273841A1/en
Priority to JP2004538876A priority patent/JP2006517181A/ja
Publication of WO2004029631A2 publication Critical patent/WO2004029631A2/de
Publication of WO2004029631A3 publication Critical patent/WO2004029631A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die Erfindung betrifft ein Verfahren zur Identifizierung der Anwesenheit eines BHS-spezifischen Proteins/Fragments in Hirnkapillar-Endothelzellen, dadurch gekennzeichnet, dass man a) frisch aus dem Gehirn isolierte Hirnkapillar-Endothelzellen durch enzymatischen Aufschluss in üblicher Weise vorreinigt, b) den in Stufe a) erhaltenen Aufschluss mit einem Lysepuffer behandelt, der vorhandene Erythrozyten und apoptotische Zellen im Wesentlichen zerstört und wenigstens 70 % der Hirnkapillar-Endothelzellen in vitaler Form erhält, c) gegebenenfalls das in Stufe b) erhaltene Produkt weiter aufreinigt, d) eine subtraktive cDNA-Bank aus den Hirnkapillar-Endothelzellen und einem Subtraktionsgewebe herstellt, e) eine cDNA-Subtraktion mittels differentieller Hybridisierung(en) durchführt, f) Klone aus der subtraktiven cDNA-Bank durch differentielle Hybridisierung hinsichtlich ihrer jeweiligen Expression verifiziert, g) zu den BHS-spezifischen Klonen aus der subtraktiven cDNA-Bank eine vollständige cDNA-Sequenz erstellt und h) das Expressionsmuster der untersuchten Klone zwischen frischen und kultivierten Hirnkapillar-Endothelzellen vergleicht und so die Anwesenheit BHS-spezifischer Proteine/Fragmente identifiziert sowie die mit diesem Verfahren identifizierten Proteine und Fragmente davon.
PCT/EP2003/009968 2002-09-11 2003-09-08 Verfahren zur identifizierung bhs-spezifischer proteine und fragmente davon WO2004029631A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/527,788 US20060172300A1 (en) 2002-09-11 2003-03-08 Method for identifying bhs-specific proteins and fragments thereof
EP03757804A EP1588172A2 (de) 2002-09-11 2003-09-08 Verfahren zur identifizierung bhs-spezifischer proteine und fragmente davon
AU2003273841A AU2003273841A1 (en) 2002-09-11 2003-09-08 Method for identifying bhs-specific proteins and fragments thereof
JP2004538876A JP2006517181A (ja) 2002-09-11 2003-09-08 Ｂｂｂ−特異的タンパク質およびその断片を同定する方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10242016A DE10242016A1 (de) 2002-09-11 2002-09-11 Verfahren zur Identifizierung BHS-spezifischer Proteine und Fragmente davon
DE10242016.5 2002-09-11

Publications (2)

Publication Number Publication Date
WO2004029631A2 WO2004029631A2 (de) 2004-04-08
WO2004029631A3 true WO2004029631A3 (de) 2006-03-02

Family

ID=31895787

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/009968 WO2004029631A2 (de) 2002-09-11 2003-09-08 Verfahren zur identifizierung bhs-spezifischer proteine und fragmente davon

Country Status (6)

Country Link
US (1) US20060172300A1 (de)
EP (1) EP1588172A2 (de)
JP (1) JP2006517181A (de)
AU (1) AU2003273841A1 (de)
DE (1) DE10242016A1 (de)
WO (1) WO2004029631A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009058997A2 (en) * 2007-11-01 2009-05-07 Biocept Inc. Non-invasive isolation of fetal nucleic acid
CA2926304C (en) * 2013-11-05 2020-04-07 F. Hoffmann-La Roche Ag Use of a reagent for the lysis of erythrocytes as well as methods and kits relating thereto
KR20210000253A (ko) * 2019-12-16 2021-01-04 재단법인 대구경북첨단의료산업진흥재단 뇌미세혈관 손상 뇌질환 진단용 바이오 마커 조성물
KR102207698B1 (ko) * 2019-06-24 2021-01-26 재단법인 대구경북첨단의료산업진흥재단 뇌미세혈관 손상 뇌질환 진단용 바이오 마커 조성물
KR102207699B1 (ko) * 2019-06-24 2021-01-26 재단법인 대구경북첨단의료산업진흥재단 뇌미세혈관 손상 뇌질환 진단용 바이오 마커 조성물
WO2020262937A1 (ko) * 2019-06-24 2020-12-30 재단법인 대구경북첨단의료산업진흥재단 뇌미세혈관 손상 뇌질환 진단용 바이오 마커 조성물
KR20210000255A (ko) * 2019-12-16 2021-01-04 재단법인 대구경북첨단의료산업진흥재단 뇌미세혈관 손상 뇌질환 진단용 바이오 마커 조성물
KR102207696B1 (ko) * 2019-06-24 2021-01-26 재단법인 대구경북첨단의료산업진흥재단 뇌미세혈관 손상 뇌질환 진단용 바이오 마커 조성물
KR102207697B1 (ko) * 2019-06-24 2021-01-26 재단법인 대구경북첨단의료산업진흥재단 뇌미세혈관 손상 뇌질환 진단용 바이오 마커 조성물
KR102100588B1 (ko) * 2019-06-24 2020-04-13 재단법인 대구경북첨단의료산업진흥재단 뇌미세혈관 손상 뇌질환 진단용 바이오 마커 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068848A2 (en) * 2000-03-01 2001-09-20 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001073003A1 (en) * 2000-03-24 2001-10-04 Biocell Laboratories Compound, composition and method for the treatment of inflammatory and inflammatory-related disorders
WO2003068054A2 (en) * 2002-02-13 2003-08-21 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Services Identification of ovarian cancer tumor markers and therapeutic targets

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268164A (en) * 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068848A2 (en) * 2000-03-01 2001-09-20 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001073003A1 (en) * 2000-03-24 2001-10-04 Biocell Laboratories Compound, composition and method for the treatment of inflammatory and inflammatory-related disorders
WO2003068054A2 (en) * 2002-02-13 2003-08-21 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Services Identification of ovarian cancer tumor markers and therapeutic targets

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AUDUS K L ET AL: "Bovine brain microvessel endothelial cell monolayers as a model system for the blood-brain barrier.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES. UNITED STATES 1987, vol. 507, 1987, pages 9 - 18, XP001179819, ISSN: 0077-8923 *
CHOI S C ET AL: "Cloning and characterization of a type II integral transmembrane protein gene, Itm2c, that is highly expressed in the mouse brain.", MOLECULES AND CELLS. KOREA (SOUTH) 31 DEC 2001, vol. 12, no. 3, 31 December 2001 (2001-12-31), pages 391 - 397, XP009026835, ISSN: 1016-8478 *
DELEERSNIJDER W ET AL: "ISOLATION OF MARKERS FOR CHONDRO-OSTEOGENIC DIFFERENTIATION USING CDNA LIBRARY SUBTRACTION MOLECULAR CLONING AND CHARACTERIZATION OF A GENE BELONGING TO A NOVEL MULTIGENE FAMILY OF INTEGRAL MEMBRANE PROTEINS", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 271, no. 32, 9 August 1996 (1996-08-09), pages 19475 - 19482, XP002917436, ISSN: 0021-9258 *
SEN T ET AL: "Glucose oxidase-induced lysis of erythrocytes", INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY, vol. 33, no. 1, 1995, pages 75 - 76, XP009026651, ISSN: 0019-5189 *
YAO XIAO-HAO ET AL: "Identification of a key protein associated with cerebral ischemia.", BRAIN RESEARCH, vol. 967, no. 1-2, 28 March 2003 (2003-03-28), pages 11 - 18, XP001180022, ISSN: 0006-8993 (ISSN print) *

Also Published As

Publication number Publication date
AU2003273841A8 (en) 2004-04-19
DE10242016A1 (de) 2004-03-25
EP1588172A2 (de) 2005-10-26
US20060172300A1 (en) 2006-08-03
JP2006517181A (ja) 2006-07-20
AU2003273841A1 (en) 2004-04-19
WO2004029631A2 (de) 2004-04-08

Similar Documents

Publication Publication Date Title
GEP20166454B (en) Sclerostin binding agents
DE954602T1 (de) Erbliches hemochromatosis-gen
WO2004029631A3 (de) Verfahren zur identifizierung bhs-spezifischer proteine und fragmente davon
DE602004030327D1 (de) Verfahren zur herstellung von präparationen rekombinanter aav-virionen, die weitgehend frei von leeren capsiden sind
ATE553125T1 (de) Herstellung eines multimeren proteins durch zellfusionsverfahren
HK1094336A1 (en) Connective tissue growth factor antibodies
WO2003042654A3 (en) Multi-parameter high throughput screening assays (mphts)
NO20092741L (no) DR6-antagonister og anvendelse derav ved behandling av neurologiske forstyrrelser
DE69926254D1 (de) Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden
WO2001098491A3 (en) Osteolevin gene polymorphisms
WO2001038487A3 (en) MOUSE ASPARTIC SECRETASE-1 (mASP1)
WO2004030622A3 (en) Method of isolation and self-assembly of small protein particles from blood and other biological materials
WO2004029072A3 (en) PrPsc -INTERACTING MOLECULES AND USES THEREOF
EA200800785A1 (ru) 4-арил-1,4-дигидро-3(2н)-изохинолиноны и 4-арил-1,2,3,4-тетрагидроизохинолины в качестве ингибиторов igf-1r и в качестве фармакологического средства в тест-системах, фармацевтическая композиция и изделие на их основе и способ лечения заболеваний, опосредованных igf-1 рецептором
DE69737996D1 (de) Methoden zur herstellung von nukleotidintegrasen
WO2000034652A8 (en) Methods of identifying point mutations in a genome
DE60314132D1 (de) Methode zur produktion monoklonaler antikörper
WO2003008441A3 (en) Moringa seed proteins
WO1999058098A8 (en) HUMAN ANTITHROMBIN IIIs AND METHODS RELATED THERETO
AU2003301804A1 (en) Dc-sign blockers and their use for preventing or treating viral infections.
DE60222405D1 (de) Verfahren zur verbesserung von proteinprodukten
WO2002099064A3 (en) Rna purification methods
WO2004005882A3 (en) Multi-parameter high throughput screening assays (mphts)
WO2002099061A3 (en) Method of treating alzheimer's disease with se-containing peptide
WO2004073731A8 (en) 14-3-3 protein for prevention and treatment of fibroproliferative disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004538876

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003757804

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003757804

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006172300

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10527788

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10527788

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2003757804

Country of ref document: EP